Axsome shares jump as settlement will keep Teva's Auvelity generic off the market until 2038
With the settlement, Teva will not market the Auvelity generic until September 30, 2038, Axsome said in a Monday press release. Entrance of the generic will be delayed by an additional six months, until March 31, 2039, if Axsome gains an FDA pediatric exclusivity extension for its treatment.
Shares of Axsome Therapeutics ( AXSM 4.36%) are up on Tuesday. The company's stock gained 4.1% as of 10:20 a.m. ET, but was ...
Axsome Therapeutics, Inc. (NASDAQ:AXSM) signed a settlement agreement with Teva Pharmaceuticals Inc (NYSE:TEVA). The ...
Axsome Therapeutics (AXSM) is climbing nearly 4% after Swiss bank UBS increased its price target on the shares to $133 from ...
Mizuho raised the firm’s price target on Axsome Therapeutics (AXSM) to $195 from $137 and keeps an Outperform rating on the shares following ...
Zacks.com on MSN15h
Axsome (AXSM) Surges 20.2%: Is This an Indication of Further Gains?Axsome (AXSM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...
The U.S. Food and Drug Administration has approved Axsome Therapeutics' migraine treatment, the company said on Thursday.
Shares of Axsome Therapeutics (NASDAQ: AXSM) are flying higher on Monday. The company's stock is up 24.7% as of 1:10 p.m. ET, ...
Deutsche Bank (ETR:DBKGn) initiated coverage on Axsome Therapeutics (NASDAQ:AXSM) shares, assigning a Buy rating and setting a price target of $176.00. The new coverage comes with a positive outlook ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback